Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether fit patients (with ECOG performance score
of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line
setting (after prior therapy with cisplatin and gemcitabine) in terms of overall survival.